CRD-740 / Cardurion - LARVOL DELTA

Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CRD-740, a PDE9 Inhibitor, in Chronic Heart Failure. (PubMed, JACC Heart Fail) - P2 | "In this initial phase 2 trial, PDE9 inhibition with CRD-740 was well tolerated and resulted in elevations of plasma and urinary cGMP on top of standard care, including sacubitril/valsartan, supporting the potential of PDE9 inhibition to enhance the beneficial effects of the natriuretic peptide receptor-cGMP pathway incremental to existing heart failure treatments. (Effectiveness of CRD-740 in Heart Failure [CARDINAL-HF]; NCT05409183)."

Clinical • Journal • P2 data • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypotension

A phase 2, randomized, double-blind, placebo-controlled study to assess the tolerability and pharmacodynamic effects of CRD-740, a PDE9 inhibitor, in participants with chronic heart failure (ESC 2024) - No abstract available

Clinical • P2 data • PK/PD data • Cardiovascular • Congestive Heart Failure • Heart Failure

A phase 2, randomized, double-blind, placebo-controlled study to assess the tolerability and pharmacodynamic effects of CRD-740, a PDE9 inhibitor, in participants with chronic heart failure (HEART FAILURE 2024) - No abstract available

Clinical • Late-breaking abstract • P2 data • PK/PD data • Cardiovascular • Congestive Heart Failure • Heart Failure

CARDINAL-HF: Effectiveness of CRD-740 in Heart Failure (clinicaltrials.gov) - P2 | N=60 | Terminated | Sponsor: Cardurion Pharmaceuticals, Inc. | N=660 ➔ 60 | Trial completion date: Jan 2024 ➔ Jul 2023 | Active, not recruiting ➔ Terminated | Trial primary completion date: Dec 2023 ➔ May 2023; Part A of the study was successfully concluded. Part B of the study was discontinued in favor of redesigned new studies.

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Cardiovascular • Congestive Heart Failure • Heart Failure

CARDINAL-HF: Effectiveness of CRD-740 in Heart Failure (clinicaltrials.gov) - P2 | N=660 | Active, not recruiting | Sponsor: Cardurion Pharmaceuticals, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Cardiovascular • Congestive Heart Failure • Heart Failure

Effect of Coadministration of Itraconazole on the Pharmacokinetics of CRD-740 (clinicaltrials.gov) - P1 | N=20 | Completed | Sponsor: Cardurion Pharmaceuticals, Inc. | Recruiting ➔ Completed

Trial completion • Cardiovascular • Heart Failure

Effect of Coadministration of Itraconazole on the Pharmacokinetics of CRD-740 (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: Cardurion Pharmaceuticals, Inc.

New P1 trial • Cardiovascular • Heart Failure

CARDINAL-HF: Effectiveness of CRD-740 in Heart Failure (clinicaltrials.gov) - P2 | N=660 | Recruiting | Sponsor: Cardurion Pharmaceuticals, Inc.

New P2 trial • Cardiovascular • Congestive Heart Failure • Heart Failure